Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 277

1.

Collaborative retrospective macula society study of photodynamic therapy for chronic central serous chorioretinopathy.

Lim JI, Glassman AR, Aiello LP, Chakravarthy U, Flaxel CJ, Spaide RF; Macula Society CSC Collaborative Study Group, Research and Education Committee and Website Committee.

Ophthalmology. 2014 May;121(5):1073-8. doi: 10.1016/j.ophtha.2013.11.040. Epub 2014 Jan 16.

PMID:
24439758
2.

Low-fluence photodynamic therapy versus ranibizumab for chronic central serous chorioretinopathy: one-year results of a randomized trial.

Bae SH, Heo J, Kim C, Kim TW, Shin JY, Lee JY, Song SJ, Park TK, Moon SW, Chung H.

Ophthalmology. 2014 Feb;121(2):558-65. doi: 10.1016/j.ophtha.2013.09.024. Epub 2013 Nov 20.

PMID:
24268858
3.

Half-fluence versus half-dose photodynamic therapy in chronic central serous chorioretinopathy.

Nicoló M, Eandi CM, Alovisi C, Grignolo FM, Traverso CE, Musetti D, Cardillo Piccolino F.

Am J Ophthalmol. 2014 May;157(5):1033-7. doi: 10.1016/j.ajo.2014.01.022. Epub 2014 Jan 30.

PMID:
24487046
4.
5.

One-year outcomes with half-dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy.

Fujita K, Imamura Y, Shinoda K, Matsumoto CS, Mizutani Y, Hashizume K, Mizota A, Yuzawa M.

Ophthalmology. 2015 Mar;122(3):555-61. doi: 10.1016/j.ophtha.2014.09.034. Epub 2014 Nov 18.

PMID:
25444637
6.

Half-fluence photodynamic therapy in chronic central serous chorioretinopathy.

Smretschnig E, Ansari-Shahrezaei S, Hagen S, Glittenberg C, Krebs I, Binder S.

Retina. 2013 Feb;33(2):316-23. doi: 10.1097/IAE.0b013e318280769c.

PMID:
23314238
7.

Association between the efficacy of half-dose photodynamic therapy with indocyanine green angiography and optical coherence tomography findings in the treatment of central serous chorioretinopathy.

Nicolò M, Zoli D, Musolino M, Traverso CE.

Am J Ophthalmol. 2012 Mar;153(3):474-480.e1. doi: 10.1016/j.ajo.2011.08.015. Epub 2011 Oct 22.

PMID:
22019224
8.

Photodynamic therapy for chronic central serous chorioretinopathy: a 4-year follow-up study.

Silva RM, Ruiz-Moreno JM, Gomez-Ulla F, Montero JA, Gregório T, Cachulo ML, Pires IA, Cunha-Vaz JG, Murta JN.

Retina. 2013 Feb;33(2):309-15. doi: 10.1097/IAE.0b013e3182670fbe.

PMID:
23095766
9.

Photodynamic therapy for chronic central serous chorioretinopathy.

Ruiz-Moreno JM, Lugo FL, Armadá F, Silva R, Montero JA, Arevalo JF, Arias L, Gómez-Ulla F.

Acta Ophthalmol. 2010 May;88(3):371-6. doi: 10.1111/j.1755-3768.2008.01408.x. Epub 2009 Nov 27.

10.

Half-time photodynamic therapy for central serous chorioretinopathy.

Tsai MJ, Hsieh YT.

Optom Vis Sci. 2014 Sep;91(9):1140-5. doi: 10.1097/OPX.0000000000000360.

PMID:
25083838
11.

A randomized pilot study of low-fluence photodynamic therapy versus intravitreal ranibizumab for chronic central serous chorioretinopathy.

Bae SH, Heo JW, Kim C, Kim TW, Lee JY, Song SJ, Park TK, Moon SW, Chung H.

Am J Ophthalmol. 2011 Nov;152(5):784-92.e2. doi: 10.1016/j.ajo.2011.04.008. Epub 2011 Jul 13.

PMID:
21742303
12.

Long-term results of half-fluence photodynamic therapy for chronic central serous chorioretinopathy.

Rouvas A, Stavrakas P, Theodossiadis PG, Stamatiou P, Milia M, Giannakaki E, Datseris I.

Eur J Ophthalmol. 2012 May-Jun;22(3):417-22. doi: 10.5301/ejo.5000051.

13.

[Photodynamic therapy for chronic central serous chorioretinopathy and diffuse retinal epitheliopathy].

Cornut PL, Quaranta-El Maftouhi M, Mauget-Faÿsse M.

J Fr Ophtalmol. 2012 Feb;35(2):82-7. doi: 10.1016/j.jfo.2011.07.005. Epub 2011 Sep 1. French.

14.

Efficacy of half-fluence photodynamic therapy depending on the degree of choroidal hyperpermeability in chronic central serous chorioretinopathy.

Lim SH, Chang W, Sagong M.

Eye (Lond). 2013 Mar;27(3):353-62. doi: 10.1038/eye.2013.13. Epub 2013 Mar 1.

15.

Standard-fluence versus low-fluence photodynamic therapy in chronic central serous chorioretinopathy: a nonrandomized clinical trial.

Reibaldi M, Cardascia N, Longo A, Furino C, Avitabile T, Faro S, Sanfilippo M, Russo A, Uva MG, Munno F, Cannemi V, Zagari M, Boscia F.

Am J Ophthalmol. 2010 Feb;149(2):307-315.e2. doi: 10.1016/j.ajo.2009.08.026. Epub 2009 Nov 6.

PMID:
19896635
16.

[Photodynamic therapy for treatment of chronic or recurrent central serous chorioretinopathy].

Li L, Yuan F, Xu GZ, Wang WJ.

Zhonghua Yan Ke Za Zhi. 2012 Feb;48(2):106-13. Chinese.

PMID:
22490944
17.
18.

Long-term chorioretinal changes after photodynamic therapy for chronic central serous chorioretinopathy.

Vasconcelos H, Marques I, Santos AR, Melo P, Pires I, Figueira J, de Abreu JF, Cachulo ML, Silva R.

Graefes Arch Clin Exp Ophthalmol. 2013 Jul;251(7):1697-705. doi: 10.1007/s00417-013-2270-2. Epub 2013 Feb 7.

PMID:
23389551
19.

Half-fluence photodynamic therapy in acute central serous chorioretinopathy.

Smretschnig E, Ansari-Shahrezaei S, Moussa S, Glittenberg C, Krebs I, Binder S.

Retina. 2012 Nov-Dec;32(10):2014-9. doi: 10.1097/IAE.0b013e318242b9ab.

PMID:
22466482
20.

Subfoveal choroidal thickness after treatment of central serous chorioretinopathy.

Maruko I, Iida T, Sugano Y, Ojima A, Ogasawara M, Spaide RF.

Ophthalmology. 2010 Sep;117(9):1792-9. doi: 10.1016/j.ophtha.2010.01.023. Epub 2010 May 15.

PMID:
20472289
Items per page

Supplemental Content

Write to the Help Desk